Libtayo Demonstrates Sustained Overall Survival Benefit in High-Risk Cutaneous Squamous Cell Carcinoma

Longer-term data, reflecting nearly four years of follow-up from the Phase 3 C-POST trial, show a further reduction in the risk of death from 14% to 37% for patients initially treated with the PD-1 inhibitor Libtayo (cemiplimab) as adjuvant therapy for high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation. These late-breaking results were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) 2026 Meeting.